Technology
Health
Biotechnology

ContraFect

$0.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0054 (1.38%) Today
-$0.0174 (-4.38%) As of 4:11 PM EDT after-hours

Why Robinhood?

You can buy or sell ContraFect and other stocks, options, ETFs, and crypto commission-free!

About CFRX

ContraFect Corporation Common Stock, also called ContraFect, is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. Read More The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Employees
20
Headquarters
Yonkers, New York
Founded
2008
Market Cap
31.56M
Price-Earnings Ratio
7.25
Dividend Yield
Average Volume
118.62K
High Today
$0.41
Low Today
$0.38
Open Price
$0.41
Volume
251.97K
52 Week High
$2.63
52 Week Low
$0.355

Collections

Technology
Health
Biotechnology
Medical
2014 IPO
US
North America

CFRX Earnings

-$0.27
-$0.20
-$0.13
-$0.06
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
-$0.11 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.